Christopher Rhodes to SOXF Transcription Factors
This is a "connection" page, showing publications Christopher Rhodes has written about SOXF Transcription Factors.
Connection Strength
1.629
-
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med. 2019 03; 7(3):227-238.
Score: 0.681
-
Response by Walters et al to Letter Regarding Article, "SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension". Circulation. 2023 11 28; 148(22):1825-1826.
Score: 0.240
-
An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis. Commun Biol. 2022 11 07; 5(1):1192.
Score: 0.224
-
The pathophysiological role of novel pulmonary arterial hypertension gene SOX17. Eur Respir J. 2021 09; 58(3).
Score: 0.207
-
Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018 04 12; 9(1):1416.
Score: 0.163
-
SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. Circulation. 2023 05 23; 147(21):1606-1621.
Score: 0.058
-
The SOX17 phenotype in pulmonary arterial hypertension: lessons for pathobiology and clinical management. Eur Respir J. 2022 12; 60(6).
Score: 0.056